Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer

Inclusion Criteria: * Man or woman * Age ≥ 18 and ≤ 80 years * Performance status of 0 or 1 according to the ECOG score of WHO * Patient with Metastatic colorectal non-curative and progression on therapy in first -line therapy containing 5-fluorouracil and bevacizumab cancer. * Patient with low or intermediate risk defined by modified Kohne's criteria * Hepatic metastases ≥ 1 cm * Evaluation Review (CT chest, abdomen and pelvis ) made in the previous 4 weeks and showing the presence of a measurable lesion according to RECIST 1.1 criteria. * Indication treatment LV5FU2 + bevacizumab validated * Patient whose understanding of the study is good * Biological values within the following limits : * Bilirubin ≤ 1.5 x upper limit of normal ( N) * AST and ALT ≤ 5 N * Creatinin ≤ 1.5 N and creatinin clearance \> 60 ml / min * Neutrophils ≥ 1.5 . 109 / L * Platelets ≥ 100 . 109 / L * Hemoglobin ≥ 9 g / dL ( even if includable patients were transfused ) . * Albumin ≥ 30 g / L * Serological hepatitis B , C and HIV negative * Information given and signed informed consent * Patient affiliated to a social security system * For women of childbearing age , the need for effective contraception. Exclusion Criteria: Related to the disease: * Other cancer within 5 years prior to entry into the trial or concomitant (except carcinoma in situ of the cervix or basal cell carcinoma of the skin ) . * Presence of brain metastasis * Prognosis estimated survival \<3 months Related to treatment : * Presence of a contraindication to bevacizumab ( major surgery in the previous 28 days , the risk of arterial thrombosis, risk of bleeding , deep vein thrombosis without effective anti- coagulant treatment or unbalanced anticoagulant treatment) Concomitant systemic * Immunotherapy , immunosuppressants, corticosteroids ≥ 1mg/kg or hormone therapy : corticosteroids administered chronically , immunosuppressive therapy, biotherapy administered under the management of inflammatory disease (anti -TNF , anti- IL6 ... ) * Hypersensitivity to one of the compounds of treatments * Latex Hypersensitivity ( the cap of the syringe containing anakinra contains dry natural rubber, a derivative of latex), which may cause allergic reactions * Peripheral neuropathy grade ≥ 2 * History of autoimmune disease or inflammatory Related to patient conditions : * Participation during or within 30 days prior to study entry to another clinical trial with an experimental molecule. * Serious disease unbalanced, underlying infection that may prevent the patient from receiving treatment * Intestinal occlusion or sub- occlusion or history of inflammatory bowel disease * Pregnancy (test mandatory inclusion pregnancy) , lactation or lack of effective contraception for men and women of childbearing age * Psychiatric disease compromising understanding of the information or the accomplishment of the study * Patient under guardianship, curatorship or judicial protection * Unable to sign the informed consent or to submit to medical follow-up for geographical, social or psychological reasons.